{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088621","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.450963+00:00","generated_at":"2026-06-12T02:38:31.181664+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organon Q2 2023 revenue $1.61B (+4% ex-FX); adj. EPS $1.31; FY guidance narrowed","bullets":["GAAP diluted EPS $0.95; non-GAAP adjusted diluted EPS $1.31 vs $1.25 prior year.","Women's Health revenue $438M (+10% ex-FX); Nexplanon up 12% ex-FX; fertility +17% ex-FX.","Biosimilars $135M (+15% ex-FX); Renflexis +20% ex-FX; Hadlima launched in US July 1.","Established Brands $995M (flat ex-FX); expects flat full-year revenue.","FY 2023 revenue guidance narrowed to $6.25-6.45B; adj. EBITDA margin 31.5%-33.0%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088621","json":"https://secwatch.observer/filing/0001104659-23-088621.json","markdown":"https://secwatch.observer/filing/0001104659-23-088621.md","text":"https://secwatch.observer/filing/0001104659-23-088621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/0001104659-23-088621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/tm2322580d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:38:31.181664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68b1e07877d87f7cd283253589e4b86076a3b665","claim":"Organon & Co. reported the second quarter ended June 30, 2023 results: revenue $1,608 million, net income $242 million, EPS $0.95. Guidance reaffirmed.","evidence_excerpt":"Organon Reports Results for the Second Quarter Ended June 30, 2023 • Second quarter 2023 revenue of $1,608 million • Second quarter 2023 diluted earnings per share of $0.95","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/0001104659-23-088621-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$1,608 million"},{"label":"Net income","value":"$242 million"},{"label":"EPS","value":"$0.95"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}